MiMedx Group (MDXG) Competitors

Bausch + Lomb (NYSE:BLCO) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.

Does the media favor BLCO or MDXG?

In the previous week, Bausch + Lomb had 5 more articles in the media than MiMedx Group. MarketBeat recorded 9 mentions for Bausch + Lomb and 4 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.69 beat Bausch + Lomb's score of 0.75 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has higher earnings & valuation, BLCO or MDXG?

MiMedx Group has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$4.83B	0.82	-$317M	-$1.03	-10.92
MiMedx Group	$352.38M	2.89	$58.23M	$0.27	25.56

Do insiders and institutionals hold more shares of BLCO or MDXG?

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 0.8% of Bausch + Lomb shares are owned by insiders. Comparatively, 1.7% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer BLCO or MDXG?

MiMedx Group received 10 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 83.61% of users gave MiMedx Group an outperform vote while only 41.00% of users gave Bausch + Lomb an outperform vote.

Company	Underperform	Outperform
Bausch + Lomb	Outperform Votes 41 41.00%	Underperform Votes 59 59.00%
MiMedx Group	Outperform Votes 51 83.61%	Underperform Votes 10 16.39%

Do analysts prefer BLCO or MDXG?

Bausch + Lomb presently has a consensus price target of $15.50, indicating a potential upside of 37.85%. MiMedx Group has a consensus price target of $12.50, indicating a potential upside of 81.16%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts plainly believe MiMedx Group is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.25
MiMedx Group	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is BLCO or MDXG more profitable?

MiMedx Group has a net margin of 23.86% compared to Bausch + Lomb's net margin of -6.62%. MiMedx Group's return on equity of 26.21% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-6.62%	3.35%	1.66%
MiMedx Group	23.86%	26.21%	18.15%

Which has more volatility and risk, BLCO or MDXG?

Bausch + Lomb has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Summary

MiMedx Group beats Bausch + Lomb on 15 of the 18 factors compared between the two stocks.